NHC Responds to Draft Guidance on Demonstrating Substantial Evidence of Effectiveness September 22, 2026 Kyle A. Diamantas, JD Acting Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 […]
Letters and Comments
NHC Submits Statement for the Record to House Committee on Energy and Commerce on ASAP Act
NHC Submits Statement for the Record to House Committee on Energy and Commerce on ASAP Act Prepared Written Testimony Randall Rutta Chief Executive Officer, National Health Council United States House […]
NHC Responds to CMS CY 2027 Physician Fee Schedule Proposed Rule
NHC Responds to CMS CY 2027 Physician Fee Schedule Proposed Rule September 14, 2026 Mehmet Oz, MD, MBA Administrator Centers for Medicare & Medicaid Services Department of Health and Human […]
NHC Responds to CMS CY 2027 OPPS Proposed Rule
NHC Responds to CMS CY 2027 OPPS Proposed Rule August 31, 2026 Mehmet Oz, MD, MBA AdministratorCenters for Medicare & Medicaid Services Department of Health and Human Services 7500 Security […]
NHC Response to 340B Drug Pricing Integrity and Affordability for Patients Act Discussion Draft
NHC Response to 340B Drug Pricing Integrity and Affordability for Patients Act Discussion Draft August 28, 2026 The Honorable Bill Cassidy Chairman Committee on Health, Education, Labor, and Pensions United […]
NHC Comments on OIG Clinical Trial Participation RFI
NHC Comments on OIG Clinical Trial Participation RFI August 24, 2026 The Honorable T. March Bell Inspector General Office of Inspector General Department of Health and Human Services Cohen Building […]
NHC Comments on CMS Proposed Rule for Medicare Drug Price Negotiation Program IPAY 2029
NHC Comments on CMS Proposed Rule for Medicare Drug Price Negotiation Program IPAY 2029 August 17, 2026 Mehmet Oz, MD, MBA Administrator Centers for Medicare & Medicaid Services Department of […]
NHC Responds to Senate RFI on Drug Costs
NHC Responds to Senate RFI on Drug Costs August 17, 2026 The Honorable Ron Wyden Ranking Member Committee on Finance United States Senate Washington, DC 20510 Dear Ranking Member Wyden: […]
NHC Comments on Medical Device User Fee Amendments Performance Goals and Procedures for fiscal years 2028 through 2032
NHC Comments on Medical Device User Fee Amendments Performance Goals and Procedures for Fiscal Years 2028 through 2032 August 6, 2026 Dockets Management Staff Food and Drug Administration 5630 Fishers […]
NHC Submits Statement for the Record to Senate Budget Committee on Medicaid
NHC Submits Statement for the Record to Senate Budget Committee on Medicaid Prepared Written Testimony Randall Rutta Chief Executive Officer National Health Council U.S. Senate, Committee on the Budget August 4, 2026 On […]